

Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis

<https://marketpublishers.com/r/AB44CE487B9EN.html>

Date: July 2017

Pages: 0

Price: US\$ 1,700.00 (Single User License)

ID: AB44CE487B9EN

Abstracts

Adult Vaccines Market is expected to be close to US\$ 20 Billion by the year 2022. Because of vaccines, some diseases (like Polio and Diphtheria) are becoming rare. Vaccination can prevent certain deadly diseases in all age groups. Almost all countries around the world have introduced efficient National Immunization Programme in their vaccination schedule to overcome the epidemics caused by vaccine-preventable diseases. WHO's Global Vaccine Action Plan, Global Immunization Vision and Strategy (GIVS), The GAVI Alliance all are putting their best to minimize the incidence of vaccine-preventable diseases which indeed is driving the adult vaccine market vigorously.

Influenza Vaccine Leads the Adult Vaccine Market for the Year 2017

Influenza vaccine is dominating the adult vaccine segment in year 2017, however it will lose its place to Pneumococcal vaccine in the coming future as admissions for pneumonia had almost tripled over the last 15 years. Other than Influenza and Pneumococcal Vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines also have considerable market share in adult vaccines market.

Considerable Growth in Immunization of Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV Vaccines

In terms of Immunization; Influenza holds the maximum share as influenza vaccination is recommended to take annually in almost all countries of the world. However, with the growing awareness and efficiency of vaccines in preventing diseases, our analysis found that there will be considerably growth in the number for people opting for Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV vaccines in future till 2022.

Administration of Vaccines Doses

Influenza Vaccine holds the topmost place while talking about the administration of vaccine doses as influenza strains change every year and people need to get an updated influenza shot each year to stay protected. Expect Influenza; Cervical Cancer (HPV), Pneumococcal and Hepatitis vaccines have remarkable administration doses.

Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis is the 2nd publication by Renub Research on Adult Vaccines Market. This 181 pages research report with 77 Figures and 32 Tables provides a complete analysis of Adult Vaccines Market, Immunization Numbers in People, Number of Vaccine Doses Administered in Adults (Disease wise) & Key Players Analysis.

Adult Vaccines in the Report have been studied from 3 Viewpoints

1. Global Adult Vaccines (Disease wise) Market & Forecast (2011 – 2022)
2. People Immunized (Disease wise) & Forecast (2011 – 2022)
3. Doses of Vaccines Administered (Disease wise) & Forecast (2011 – 2022)

Vaccines Studied in the Report are as Follows:

1. Influenza
2. Cervical Cancer
3. Zoster (Shingles)
4. MMRV (Measles, Mumps, Rubella and Varicella)
5. Pneumonia
6. Meningitis
7. Hepatitis
8. DTap (Diphtheria, Tetanus, Pertussis)
9. Travel & Miscellaneous Vaccine

Companies Vaccines Sales and Forecast

1. GlaxoSmithKline, plc Sales & Forecast (2011 – 2022)
2. Merck & Co. Sales & Forecast (2011 – 2022)
3. Sanofi Pasteur's Sales & Forecast (2011 – 2022)
4. Pfizer, Inc.'s Sales & Forecast (2011 – 2022)
5. Others Vaccines

Key Questions Answered In This Report

What will be the Market Size of Global Adult Vaccine by the year 2022?

What are the Key Drivers & Challenges for Adult Vaccines Market?

Who are the key players in Adult Vaccine Market?

What products are in key Players Pipeline?

Contents

1 RESEARCH FINDINGS

2 GLOBAL – ADULT VACCINES MARKET AND FORECAST

3 GLOBAL – ADULT VACCINES MARKET SHARE AND FORECAST

4 WORLDWIDE – ADULT IMMUNIZED NUMBERS AND FORECAST

5 WORLDWIDE – ADULT IMMUNIZED SHARE AND FORECAST

6 WORLDWIDE – DOSES OF ADULT VACCINES ADMINISTERED AND FORECAST

7 WORLDWIDE – DOSES OF VACCINES ADMINISTERED TO ADULT SHARE AND FORECAST

8 WORLDWIDE – VACCINE COMPANIES MARKET SHARE AND FORECAST

9 DISEASE WISE – ADULT VACCINES MARKET AND FORECAST

9.1 Influenza – Adult Vaccines Market and Forecast

9.2 Cervical Cancer (HPV) – Vaccines Market and Forecast

9.3 Zoster (Shingles) – Vaccines Market and Forecast

9.4 MMRV (Measles, Mumps, Rubella, and Varicella Vaccine) – Adult Vaccines Market and Forecast

9.5 Pneumococcal – Adult Vaccines Market and Forecast

9.6 Meningococcal – Adult Vaccines Market and Forecast

9.7 Hepatitis – Adult Vaccines Market and Forecast

9.8 Tdap – Adult Vaccines Market and Forecast

9.9 Travel and Miscellaneous – Vaccines Market and Forecast

10 DISEASE WISE – ADULT IMMUNIZED NUMBERS AND FORECAST

10.1 Influenza – Number of Adults Immunized and Forecast

10.2 Cervical Cancer (HPV) – People Immunized and Forecast

10.3 Zoster (Shingles) – Number of People Immunized and Forecast

10.4 MMRV – Number of Adults Immunized and Forecast

- 10.5 Pneumococcal – Number of Adults Immunized and Forecast
- 10.6 Meningococcal – Number of Adults Immunized and Forecast
- 10.7 Hepatitis – Number of Adults Immunized and Forecast
- 10.8 TdaP – Number of Adults Immunized and Forecast

11 DISEASE WISE – DOSES OF VACCINES ADMINISTERED AND FORECAST

- 11.1 Influenza – Doses of Adult Vaccines Administered and Forecast
- 11.2 Cervical Cancer (HPV) – Doses of Vaccines Administered and Forecast
- 11.3 Zoster (Shingles) – Doses of Vaccines Administered and Forecast
- 11.4 MMRV – Doses of Adult Vaccines Administered and Forecast
- 11.5 Pneumococcal – Doses of Adult Vaccines Administered and Forecast
- 11.6 Meningococcal – Doses of Adult Vaccines Administered and Forecast
- 11.7 Hepatitis – Doses of Adult Vaccines Administered and Forecast
- 11.8 TdaP – Doses of Adult Vaccines Administered and Forecast

12 DISEASE WISE - IMMUNIZATION PROFILE

- 12.1 Immunization Coverage (%) in Infants (2005 – 2015)
- 12.2 Global Immunization Profile (2011 – 2015)
- 12.3 Regional Immunization Profile (2001 – 2015)
 - 12.3.1 Measles – Number of Cases Reported
 - 12.3.2 Mumps – Number of Cases Reported
 - 12.3.3 Rubella – Number of Cases Reported
 - 12.3.4 Rubella (CRS) – Number of Cases Reported
 - 12.3.5 Diphtheria – Number of Cases Reported
 - 12.3.6 Tetanus (Neonatal) – Number of Cases Reported
 - 12.3.7 Tetanus (Total) – Number of Cases Reported
 - 12.3.8 Pertussis – Number of Cases Reported
 - 12.3.9 Polio – Number of Cases Reported
 - 12.3.10 Yellow Fever – Number of Cases Reported
 - 12.3.11 Japanese encephalitis – Number of Cases Reported, 2006 - 2015

13 VACCINES KEY PLAYERS SALES AND FORECAST

- 13.1 GlaxoSmithKline, plc.'s Vaccines Sales and Forecast
- 13.2 Merck & Co. Vaccines Sales and Forecast
- 13.3 Sanofi Pasteur's (France) Vaccines Sales and Forecast
- 13.4 Pfizer, Inc.'s Vaccines Sales and Forecast

13.5 Others Vaccines Sales and Forecast

14 VACCINES – PRODUCTS AND PIPELINE

14.1 GSK Vaccine Product Pipeline

14.2 Merck Vaccine Product Pipeline

14.3 Sanofi Vaccine Product Pipeline

14.4 Pfizer Vaccine Product Pipeline

15 TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY

16 VACCINES AND REGULATOR’S INTERVENTIONS

16.1 Making and Meeting Standards of Quality and Safety

16.2 Vaccine Funding

17 VACCINE MARKET DRIVERS

17.1 Inclusion in National Immunization Schedule

17.2 Growing Immunization Coverage for HPV Vaccines

17.3 Increase in Prevalence of Infectious Diseases

17.4 Global Immunization Vision and Strategy (GIVS)

17.5 GAVI Model Fuelling Vaccine Manufacturers

17.5.1 The Partnership Model

17.5.2 The Business Model

17.6 Increasing Vaccine Availability in United States

17.7 The Vaccine Safety Data link Project

17.8 The Vaccine Injury Compensation Program

17.9 Transforming of Vaccine Technologies

17.1 Global Vaccine Action Plan by WHO (2011 - 2020)

17.11 Continuous Focus on Effective Communication Strategies

18 VACCINES MARKET CHALLENGES

18.1 Hurdles to Optimal use of Licensed Vaccines

18.1.1 Technical Obstacles

18.1.2 Economic Obstacles

18.1.3 Cultural Obstacles

18.2 Complexity of Vaccine Development & Approval System Thwarts Product

Development

18.2.1 Legal Obstacles

18.2.2 General Technical Barriers

18.2.3 Economic Barriers

18.2.4 Regulatory Barriers

18.3 Shortening the Timeline for Vaccine Development

18.4 Refusal/Resistance to Vaccination

18.4.1 Vaccine Adverse Event Reporting System

18.5 Vaccine Shortages and Delays

18.6 Obstacles in Vaccine Research & Development

18.7 Barriers to New Entrants in the Vaccines Market

LISTS OF TABLES

Table 2-1: Vaccine Recommendations

Table 2-2: Other Recommended Vaccines

Table 3-1: Worldwide – Adult Vaccines Market Share (Percent), 2011 - 2016

Table 3-2: Worldwide – Adult Vaccines Market Share (Percent), 2017 - 2022

Table 5-1: Worldwide – Adult Immunized Share (Percent), 2011 - 2016

Table 5-2: Worldwide – Forecast for Adult Immunized Share (Percent), 2017 – 2022

Table 7-1: Worldwide – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2016

Table 7-2: Worldwide – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2017 - 2022

Table 12-1: Worldwide – Number of Reported Cases, 2011 – 2015

Table 12-2: Measles – Number of Cases Reported, 2001 – 2015

Table 12-3: Mumps – Number of Cases Reported, 2001 - 2015

Table 12-4: Rubella – Number of Cases Reported, 2001 - 2015

Table 12-5: Rubella (CRS) – Number of Cases Reported, 2001 - 2015

Table 12-6: Diphtheria – Number of Cases Reported, 2001 - 2015

Table 12-7: Tetanus (Neonatal) – Number of Cases Reported, 2001 – 2015

Table 12-8: Tetanus (Total) – Number of Cases Reported, 2001 - 2015

Table 12-9: Pertussis – Number of Cases Reported, 2001 - 2015

Table 12-10: Polio – Number of Cases Reported, 2001 - 2015

Table 12-11: Yellow Fever – Number of Cases Reported, 2001 - 2015

Table 12-12: Japanese encephalitis – Number of Cases Reported, 2006 - 2015

Table 14-1: Merck Vaccine Product Pipeline

Table 14-2: Sanofi Vaccine Product Pipeline

Table 14-3: Pfizer Vaccine Product Pipeline

Table 15-1: Vaccine Mergers & Acquisitions

Table 17-1: United States Immunization Schedule

Table 17-2: Afghanistan Immunization Schedule

Table 17-3: Norway Immunization Schedule

Table 17-4: India Immunization Schedule

Table 17-5: Vietnam Immunization Schedule

Table 17-6: Worldwide – Total Future Deaths Averted through Vaccination (Million),
2011 – 2020

Table 17-7: Goal-Level Indicators, 2015 & 2020

Table 17-8: Improvement Strategies or Requirements – the Joint Commission and the
Project's Collaborating Organizations

List Of Figures

LIST OF FIGURES

Figure 2-1: Worldwide – Adult Vaccines Market (Billion US\$), 2011 – 2016

Figure 2-2: Worldwide – Forecast for Adult Vaccines Market (Billion US\$), 2017 – 2022

Figure 4-1: Worldwide – Adult Immunized (Million), 2011 – 2016

Figure 4-2: Worldwide – Forecast for Adult Immunized (Million), 2017 – 2022

Figure 6-1: Worldwide – Doses of Adult Vaccines Administered (Million), 2011 - 2016

Figure 6-2: Worldwide – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022

Figure 8-1: Worldwide – Key Players Vaccines Market Share (Percent), 2011 - 2016

Figure 8-2: Worldwide – Forecast for Key Players Vaccines Market Share (Percent), 2017 - 2022

Figure 9-1: Influenza – Adult Vaccines Market (Billion US\$), 2011 - 2016

Figure 9-2: Influenza – Forecast for Adult Vaccines Market (Billion US\$), 2017 – 2022

Figure 9-3: Cervical Cancer (HPV) – Vaccines Market (Billion US\$), 2011 – 2016

Figure 9-4: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US\$), 2017 - 2022

Figure 9-5: Zoster (Shingles) – Vaccines Market (Billion US\$), 2011 - 2016

Figure 9-6: Zoster (Shingles) – Forecast for Vaccines Market (Billion US\$), 2017 - 2022

Figure 9-7: MMRV – Adult Vaccines Market (Million US\$), 2011 – 2016

Figure 9-8: MMRV – Forecast for Adult Vaccines Market (Million US\$), 2017 – 2022

Figure 9-9: Pneumococcal – Adult Vaccines Market (Billion US\$), 2011 - 2016

Figure 9-10: Pneumococcal – Forecast for Adult Vaccines Market (Billion US\$), 2017 – 2022

Figure 9-11: Areas with Frequent Epidemics of Meningococcal Meningitis

Figure 9-12: Meningococcal – Adult Vaccines Market (Million US\$), 2011 – 2016

Figure 9-13: Meningococcal – Forecast for Adult Vaccines Market (Million US\$), 2017 - 2022

Figure 9-14: Hepatitis – Adult Vaccines Market (Billion US\$), 2011 - 2016

Figure 9-15: Hepatitis – Forecast for Adult Vaccines Market (Billion US\$), 2017 - 2022

Figure 9-16: Tdap – Adult Vaccines Market (Million US\$), 2011 - 2016

Figure 9-17: Tdap – Forecast for Adult Vaccines Market (Million US\$), 2017 - 2022

Figure 9-18: Travel and Miscellaneous – Vaccines Market (Billion US\$), 2011 - 2016

Figure 9-19: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US\$), 2017 - 2022

Figure 10-1: Influenza – Number of Adults Immunized (Thousand), 2011 - 2016

Figure 10-2: Influenza – Forecast for Number of Adults Immunized (Thousand), 2017 -

2022

Figure 10-3: Cervical Cancer – Number of People Immunized (Thousand), 2011 - 2016

Figure 10-4: Cervical Cancer – Forecast for Number of People Immunized (Thousand), 2017 - 2022

Figure 10-5: Zoster (Shingles) – Number of People Immunized (Thousand), 2011 - 2016

Figure 10-6: Zoster (Shingles) – Forecast for Number of People Immunized (Thousand), 2017 - 2022

Figure 10-7: MMRV – Number of Adults Immunized (Thousand), 2011 - 2016

Figure 10-8: MMRV – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022

Figure 10-9: Pneumococcal – Number of Adults Immunized (Thousand), 2011 - 2016

Figure 10-10: Pneumococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022

Figure 10-11: Meningococcal – Number of Adults Immunized (Thousand), 2011 - 2016

Figure 10-12: Meningococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022

Figure 10-13: Hepatitis – Number of Adults Immunized (Thousand), 2011 - 2016

Figure 10-14: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022

Figure 10-15: Tdap – Number of Adults Immunized (Thousand), 2011 - 2016

Figure 10-16: Tdap – Number of Adults Immunized (Thousand), 2017 - 2022

Figure 11-1: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2016

Figure 11-2: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022

Figure 11-3: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2016

Figure 11-4: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022

Figure 11-5: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2016

Figure 11-6: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022

Figure 11-7: MMRV – Doses of Adult Vaccines Administered (Million), 2011 - 2016

Figure 11-8: MMRV – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022

Figure 11-9: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2016

Figure 11-10: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022

Figure 11-11: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 -

2016

Figure 11-12: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022

Figure 11-13: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2016

Figure 11-14: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022

Figure 11-15: Tdap – Doses of Adult Vaccines Administered (Million), 2011 - 2016

Figure 11-16: Tdap – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022

Figure 12-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010

Figure 12-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015

Figure 13-1: GlaxoSmithKline, plc.'s Vaccines Sales (Billion US\$), 2011 - 2016

Figure 13-2: Forecast for GlaxoSmithKline, plc.'s Vaccines Sales (Billion US\$), 2017 - 2022

Figure 13-3: Merck & Co. Vaccines Sales (Billion US\$), 2011 - 2016

Figure 13-4: Forecast for Merck & Co. Vaccines Sales (Billion US\$), 2017 - 2022

Figure 13-5: Sanofi Pasteur's Vaccines Sales (Billion US\$), 2011 - 2022

Figure 13-6: Forecast for Sanofi Pasteur's Vaccines Sales (Billion US\$), 2017 - 2022

Figure 13-7: Pfizer, Inc.'s Vaccines Sales (Billion US\$), 2011 - 2016

Figure 13-8: Forecast for Pfizer, Inc.'s Vaccines Sales (Billion US\$), 2017 - 2022

Figure 13-9: Others Vaccines Sales (Billion US\$), 2011 - 2016

Figure 13-10: Forecast for Others Vaccines Sales (Billion US\$), 2017 - 2022

Figure 14-1: GSK Vaccine Product Pipeline

Figure 17-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule

Figure 17-2: Number of Cases of Diphtheria, Pertussis, Tetanus & Measles by Major Region Worldwide, 2013

Figure 17-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers

Figure 17-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers

Figure 17-5: US Retail Clinics Expected to Surge by 2017

I would like to order

Product name: Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis

Product link: <https://marketpublishers.com/r/AB44CE487B9EN.html>

Price: US\$ 1,700.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB44CE487B9EN.html>